Clinical Cancer Research Targets Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Al Moustafa, A.-E.
Right arrow Articles by O’Connor-McCourt, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Al Moustafa, A.-E.
Right arrow Articles by O’Connor-McCourt, M.
Clinical Cancer Research Vol. 5, 681-686, March 1999
© 1999 American Association for Cancer Research

Experimental Therapeutics, Preclinical Pharmacology

Up-Regulation of E-Cadherin by an Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Lung Cancer Cell Lines1

Ala-Eddin Al Moustafa2, Cedric Yansouni, Moulay A. Alaoui-Jamali and Maureen O’Connor-McCourt

National Research Council Canada, Biotechnology Research Institute, Montréal, Québec, H4P 2R2 Canada and Department of Biochemistry, McGill University, Montréal, Québec, Canada [A-E. A., C. Y., M. O-M.]; and Lady Davis Institute for Medical Research of the Sir Mortimer B. Davis-Jewish General Hospital, Departments of Medicine and Oncology, and McGill Center for Translational Research in Cancer, Montréal, Québec, H3T 1E2 Canada [M. A. A-J.]


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS AND DISCUSSION
 REFERENCES
 
Many human epithelial carcinomas are characterized by the overexpression and constitutive activation of the epidermal growth factor receptor (EGF-R) via an autocrine signaling loop. We have investigated the effects of a ligand-blocking monoclonal antibody (mAb) against the EGF-R LA1 on selected parameters of human lung cancer cell lines (H322 and H661) and normal human bronchial epithelial (NHBE) cells. Using Western blot analysis, we show that H322 and NHBE cell lines express comparable levels of EGF-R/p170erbB-1. The LA1 mAb against EGF-R inhibits growth, induces differentiation to a more epithelial phenotype, reduces the constitutive activation of EGF-R, and up-regulates epithelial cadherin glycoprotein expression in H322 and NHBE cells. In contrast, LA1 had no effect on either growth, differentiation, receptor tyrosine phosphorylation, or the expression of adhesion molecules in H661 cells, which is consistent with our finding that this cell line does not express detectable levels of EGF-R. These studies demonstrate that a blocking anti-EGF-R mAb can regulate proliferation, differentiation, and the expression of cell adhesion molecules in human bronchial epithelial cells. Our findings suggest possible therapeutic avenues for the treatment of invasive carcinomas via the blockade of EGF-R with antibodies.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS AND DISCUSSION
 REFERENCES
 
Carcinomas are tumors of epithelial origin and represent over 90% of human cancers. A common feature of carcinomas is the overexpression of members of the EGF-R3 family, which is strongly correlated with a poor clinical prognosis (1 , 2) . Coexpression of EGF-R and one of its ligands, TGF-{alpha}, has also been demonstrated in human carcinomas and cell lines, suggesting a possible role for an EGF-R/TGF-{alpha} autocrine loop in human carcinogenesis (3 , 4) . This autocrine signaling loop and the overexpression of EGF-R have both been demonstrated in human lung cancer cells (5 , 6) . Anti-EGF-R-inactivating antibodies bind to EGF-R with high affinity, block the binding of EGF-R with its ligands, reduce phosphorylation of EGF-R, and inhibit the growth of epidermoid, prostate, colon, and gastric cancer cells (7, 8, 9, 10) . Accordingly, it has been suggested that inhibitors of EGF-R tyrosine kinase are potentially useful as therapeutic agents in the treatment of these cancers (11 , 12) .

E-cadherin is a cell-cell adhesion molecule that connects epithelial cells via homotypic calcium-dependent interactions (13) . Decreased E-cadherin expression or function correlates with an enhanced aggressiveness and invasiveness of many carcinomas (14) . Previous studies have revealed an inverse relationship between EGF-R activation and E-cadherin expression patterns in human oesophageal, cutaneous squamous carcinoma, and breast cancer cells (15, 16, 17) .

In this study, we examined the effects of the ligand-blocking anti-EGF-R mAb LA1 on selected parameters of human lung cancer cell lines and NHBE cells. These cell lines were chosen because of their particular levels of EGF-R expression. Both the H322 and NHBE lines express comparable amounts of EGF-R, whereas none is detectable in H661 cells. We found that treatment with the LA1 antibody induces the up-regulation of E-cadherin expression, induces morphological change, inhibits cell proliferation, and reduces the constitutive activation of EGF-R in H322 and NHBE cells. This is the first demonstration that a blockade of EGF-R by an antibody results in differentiation and the up-regulation of E-cadherin. Our results suggest possible therapeutic roles for EGF-R-blocking antibodies in the treatment of invasive lung carcinomas by their ability to up-regulate the expression of cell adhesion molecules such as E-cadherin.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS AND DISCUSSION
 REFERENCES
 
Cell Culture
The human lung cancer cell lines H322 and H661 were obtained from the American Type Tissue Culture. These cell lines were cultured in DMEM with 5% FBS and incubated at 37°C in a 5% CO2 atmosphere. The NHBE cells were obtained from Clonetics (CC-2541; Normal Human Cell Systems) and were maintained in KSFM medium (Canadian Life Technologies, Inc.) without supplements.

Growth Assay
Growth curves were established by measuring the incorporation of [3H]methylthymidine into the acid insoluble fraction of cellular extracts. Briefly, ~2 x 104 cells were plated in either 2 ml of KSFM (NHBE) or 2 ml of DMEM 5% FBS (H322 and H661) into individual wells of 12-well tissue culture plates. One day later, the medium was changed either with fresh medium (control) or medium with various concentrations of anti-EGF-R mAb (0.1, 0.5, 1, and 2 µg/ml; LA1; mouse monoclonal IgG1 reacts with external domain of EGF-R; Upstate Biotechnology, Inc.). Mouse anti-IgG1 (1 µg/ml; Becton Dickinson Canada, Inc.) was used as control for the effects of mAb LA1. Cells were allowed to grow for 3 days after treatment. [3H]methylthymidine (1 µCi/ml; Amersham Corp.) was added during the last 20–24-h period. After multiple washings in cold PBS, 10% trichloroacetic acid, and 95% ethanol, the plates were allowed to dry for 2 h. Cells were solubilized in 2% SDS, and the radioactivity was quantitated by liquid scintillation mixture (ICN Biomedical, Inc). The experimental points were determined in triplicates.

Morphological changes were examined by phase-contrast microscopy using 2 x 104 cells cultured in 2 ml of KSFM (NHBE) or 2 ml of DMEM 5% FBS (H322 and H661). One day later, the medium was changed either with fresh medium (control) or medium with 1 µg/ml of anti-EGF-R mAb LA1. Mouse anti-IgG1 (1 µg/ml) was used as control for the effects of mAb LA1. The cells were examined every day for 3 days.

Clonogenic Assay
H322, H661, and NHBE cells (5 x 103) were placed in medium containing 0.5% agar with 1 µg/ml LA1 mAb or 1 µg/ml mouse anti-IgG1 as control and plated over a layer of medium containing 0.7% agar. The cultures were examined every 1–2 days for 2 weeks.

Immunoblot Analysis
Equal amounts of protein (25 µg) were subjected to electrophoresis through a 7.5% SDS-PAGE gel and transferred to a nitrocellulose membrane (Xymotech). The membrane was blocked overnight in PBS containing 3% dried milk. The membrane was then probed for 2 h at room temperature with anti-EGF-R mAb LA1 (Upstate Biotechnology, Inc.), washed three times with PBS, and incubated for 1 h with a rabbit antimouse IgG coupled to alkaline phosphatase (Canadian Life Technologies, Inc.), followed by alkaline phosphatase substrate detection (Vector Laboratories, Inc.).

Cell Lysis and Immunoprecipitation
Cells were grown with or without 1 µg/ml LA1 antibody. Cells were washed with cold PBS and lysed on ice for 30 min in lysis buffer [120 mM Tris-HCl (pH 7.4), 135 mM Nacl, 1 mM EDTA, 1% NP40, and 0.1% SDS] supplemented with the tyrosine-phosphatase inhibitor sodium orthovanadate (1 mM) and the protease inhibitors aprotinin (10 ng/ml) and PMSF (1 mM). Nuclei and insoluble material were removed by centrifugation at 13000 x g for 10 min at 4°C. Equal amounts of protein (300 µg) were precipitated with anti-EGF-R mAb (clone EGF-R; Amersham Canada Ltd.) and protein G-Sepharose (Pharmacia) overnight at 4°C. Immune complexes were separated by SDS-PAGE and immunoblotted with antiphosphotyrosine mouse mAb 4G10 (Upstate Biotechnology, Inc.)

Immunofluorescence Staining and Flow Cytometric Analysis
Cells were grown with or without 1 µg/ml LA1 antibody for 72 h and washed with PBS. Cells were then harvested by trypsinization, washed, and fixed in 3.7% formaldehyde for 10 min. Fixed cells were hydrated in PBS, permeabilized with 0.05% Triton X-100 for 1 min, and treated with an anti-E-cadherin mAb (Uvomorulin; ICN Biomedical, Inc.) for 60 min, as previously described (18) . Finally, cells were washed and resuspended in 1 ml of PBS. All steps were carried out at 4°C after trypsinization. A minimum of 1 x 104 cells was analyzed using a FAC-Scan flow cytometer (Beckman Coulter).


   RESULTS AND DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS AND DISCUSSION
REFERENCES
 
EGF-R/P170erbB-1 Expression in Human Lung Cancer and NHBE cell lines
The lung cancer cell lines H322 and H661 were chosen for comparison with NHBE cells. As shown by Western blot analysis, the H322 and NHBE cell lines express similar amounts of EGF-R (Fig. 1)Citation . EGF-R was not detectable by Western blot in H661 cells (Fig. 1)Citation . Tsao et al. (19) have previously reported that normal bronchial epithelial and immortalized HBE4-E6E7 cells express comparable levels of EGF-R mRNA. In this experiment, we show that NHBE cells and the lung cancer cell line H322 express similar levels of EGF-R protein.



View larger version (56K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Expression of EGF-R/P170erbB-1 in lung cancer cell lines H322 and H661, and NHBE cells. Equal amounts of protein were used to compare the levels of EGF-R expression in these cell lines by immunoblot analysis. Protein samples were loaded on a 7.5% SDS-PAGE gel and immunoblotted with the LA1 antibody, as detailed in "Materials and Methods." Lane 1, H322; Lane 2, H661; Lane 3, NHBE.

 
The anti-EGF-R mAb LA1 Inhibits Cell Growth and Tyrosine Phosphorylation of EGF-R in H322 and NHBE Cell Lines
The present study sought to examine the effects of the anti-EGF-R LA1 neutralizing mAb on EGF-R-mediated cell activities in NHBE cells and the lung cancer cell lines H322 and H661. The H661 cell line was used as a negative control because it does not express detectable levels of EGF-R. The LA1 neutralizing mAb has been reported to compete with ligands for receptor binding (19 , 20) . We demonstrate that this antibody inhibits the proliferation of H322 and NHBE cell lines, whereas 1 µg/ml mouse anti-IgG1, as a control treatment, does not affect the proliferation of these cells (data not shown). Fig. 2Citation shows that the proliferation of both normal lung cells and H322 cancer cells relies on EGF-R activation. Conversely, the LA1 antibody does not affect the proliferation of the H661 cell line, in which there is no EGF-R, showing that the antiproliferative effect of LA1 is, indeed, mediated by blocking EGF-R (Fig. 2)Citation .



View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Effect of LA1 antibody on cell growth and DNA synthesis of H322, H661, and NHBE cells. Cells (2 x 104) were seeded in triplicate in 2 ml of KSFM medium (NHBE) or DMEM with 5% FBS (H322 and H661), to which increasing concentrations of LA1 antibody were added (0, 0.1, 0.5, 1, and 2 µg/ml). After 3 days of treatment, DNA synthesis of all three cell types was determined by [3H]thymidine incorporation. Bars, SDs of each point.

 
We next investigated the effect of the LA1 antibody on the activation and phosphorylation of EGF-R in H322 and NHBE cells. Immunoprecipitation with an anti-EGF-R mAb, followed by Western blotting with an antiphosphotyrosine mAb, indicated that treatment with the LA1 antibody reduces the tyrosine phosphorylation of EGF-R in the H322 and NHBE cell lines (Fig. 3)Citation . LA1 slightly up-regulates EGF-R expression in H322 and NHBE cells, but not in H661 cells (data not shown). Others have shown that anti-EGF-R-inactivating antibodies bind to EGF-R with high affinity and inhibit the growth of epidermoid, prostate, colon, and gastric cancer cells (7, 8, 9, 10) . Here we report evidence that anti-EGF-R antibodies reduce the constitutive activation of EGF-R in lung cancer and normal lung cells, resulting in inhibition of their proliferation. This study suggests that the expression and constitutive activation of the EGF-R are essential for the proliferation of both NHBE cells and cancer cells.



View larger version (19K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. The LA1 anti-EGF-R antibody inhibits the constitutive tyrosine phosphorylation of EGF-R/P170erbB-1 (top band) in H322 and NHBE cells. No EGF-R was detected in H661 cells. Cells were grown for 3 days in either the absence (-) or presence (+) of 1 µg/ml LA1 antibody. Cell lysates were immunoprecipitated with anti-EGF-R antibody and analyzed by immunoblotting with antiphosphotyrosine antibody.

 
Effects of LA1 mAb on the Morphology and the Clonogenicity of H322, H661, and NHBE Cells
In the absence of LA1 mAb, H322, H661, and NHBE cells displayed an epithelial-like morphology. H322 and H661 form multilayered islands of cells, in contrast to NHBE cells, which form monolayers. Treatment for 3 days with 1 µg/ml of LA1 caused decreases in cell proliferation and led to morphological change in the H322 and NHBE cells, but not in H661. H322 and NHBE cells flattened in appearance and presented an increase in cell-cell contacts. Fig. 4Citation shows the changes in H322 and H661 to a more epithelial morphology after 3 days of treatment with 1 µg/ml LA1 mAb. In contrast, EGF induces the epithelial-fibroblastoid conversion of H322 and NHBE cells, and reduces the expression of the cell-cell adhesion molecule E-cadherin (Fig. 4)Citation .4 Solic and Davies (21) have reported that EGF can induce the conversion of colon carcinoma cells to cells with a mesenchymal phenotype and reduce the adhesion molecule expression in vitro. We have demonstrated that the epidermal growth factor family of ligands (EGF, TGF-{alpha}, heparin-binding EGF-like factor, and ß-cellulin) induce the epithelial-fibroblastoid conversion of an immortalized human bronchial epithelial cell line (HBE4-E6E7). These ligands induce a loss of, or a reduction in, the expression of the cell-cell adhesion molecules E-cadherin and desmoplakin. This is accompanied by an overexpression of intermediate filament proteins of mesenchymal cells.5Citation



View larger version (121K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. LA1 antibody induces a more epithelial differentiation of the H322 and NHBE, but not of the H661 cells. Untreated cells or cells treated with 1 µg/ml mouse anti-IgG1 presented an epithelial-like cell phenotype (A and B), whereas a 72-h treatment with LA1 mAb (1 µg/ml) induces a more epithelial differentiation, resulting in a flatter cell morphology (C). In contrast, a 72-h treatment with EGF (20 ng/ml) induces the epithelial-fibroblastoid conversion of H322 and NHBE cell lines, but not H661 cells (D).

 


View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. LA1 anti-EGF-R antibody up-regulates E-cadherin expression in H322 and NHBE, but not in H661 cells. E-cadherin expression was determined using fluorescence-activated cell sorting analysis with an anti-E-cadherin antibody. LA1 treatment increased the expression of E-cadherin in H322 (A) and NHBE (C) cell lines. E-cadherin expression in H661 cells was unchanged by LA1 treatment (B). Cells were grown in the absence (gray) or presence (black) of 1 µg/ml LA1 antibody for 3 days.

 
H322 and NHBE cells were unable to form colonies in soft agar whether in the presence or absence of LA1 mAb. H661 cells displayed a very low colony-forming efficiency in agar culture. Treatment with 1 µg/ml LA1 does not affect the formation of H661 cell colonies in soft agar (data not shown).

E-cadherin Expression Is Regulated by the Anti-EGF-R mAb LA1
In epithelial tissues, E-cadherin is required for the assembly of cells into multiple layers, as well as the establishment and maintenance of an epithelial phenotype (22 , 23) . There is evidence that E-cadherin also acts as a suppressor of tumor invasion and metastasis (14 , 24) . Recent studies have reported that the activation of some receptor tyrosine kinases, including EGF-R, affects the adhesive function of E-cadherin via the ß-catenin pathway (25 , 26) . We treated H322, H661, and NHBE cells with the LA1 antibody to determine whether the inhibition of EGF-R activation by a neutralizing mAb affects E-cadherin expression patterns. All three cell lines were treated with LA1 antibody for 3 days and examined using immunofluorescence staining with an anti-E-cadherin mAb and flow cytometric analysis. Untreated cells, as well as those treated with 1 µg/ml mouse anti-IgG1 cells, were shown to express low levels of E-cadherin. In contrast, significantly and reproducibly high levels of E-cadherin were expressed in H322 and NHBE cells treated with LA1 mAb. No effect was observed in H661 cells (Fig. 5)Citation , which do not express the EGF-R. Results similar to those obtained using immunofluorescent staining were obtained using Western blot analysis with an anti-E-cadherin mAb in the same cell lines (data not shown).

The EGF-R is expressed in high levels in the majority of human lung carcinomas and cell lines (5 , 6) . We report here that normal NHBE and tumorigenic H322 human lung cell lines express comparable levels of EGF-R, whereas tumorigenic H661 cells express no detectable EGF-R. We examined the effects of an anti-EGF-R mAb, LA1, on these cell lines. The neutralization of EGF-R by this mAb was found to induce differentiation, inhibit proliferation, and induce the overexpression of E-cadherin only in the cell lines that express EGF-R. We observed that the LA1 antibody up-regulates E-cadherin expression in an immortalized human bronchial epithelial cell line.5 Other studies have shown that anti-EGF-R mAbs are capable of inhibiting growth of epidermoid, prostatic, colon, and gastric cancer cells (7, 8, 9, 10) . In addition, anti-EGF-R mAbs have previously been shown to induce G1 arrest and up-regulate the cyclin-dependent kinase inhibitor p27KIP1 in prostatic cancer cell lines (8 , 27) .

Although EGF-R is overexpressed in several other types of human cancers, it is not known whether blocking EGF-R in these cell-types results in an up-regulation of E-cadherin expression similar to the effect we observe in lung cancer cells. Preliminary experiments in human breast MDA-MB-231, epidermis cancer A431, and lung cancer H460 cell lines treated with the blocking EGF-R mAb LA1, confirm our observed up-regulation of E-cadherin expression.6 A recent study of the human breast cancer cell line MDA-MB-468, by Hazan and Norton (28) , shows that inactivation of EGF-R induces the interaction of E-cadherin adhesion complexes with the actin-based cytoskeleton. These authors also demonstrated a large increase in cell aggregation after monoclonal anti-EGF-R treatment, but did not show an up-regulation of E-cadherin expression.

Our study is the first evidence demonstrating that treatment with an EGF-R-inactivating mAb induces differentiation to a more epithelial phenotype and up-regulates the expression of E-cadherin in normal and tumorigenic human lung cells. This observation is significant in light of the fact that a key event in carcinogenesis and metastasis is the down-regulation of cell-cell adhesion molecules, such as E-cadherin. Potential therapeutic strategies involving the up-regulation of E-cadherin by EGF-R-blocking antibodies must consider the effect we show on normal cells. Studies where control animals have been treated with anti-EGF-R mAbs have not indicated any resulting pathogenesis and suggest that these agents may not hinder normal cells in vivo (12) . Finally, our results imply that the induction of E-cadherin expression by EGF-R-blocking antibodies represents a possible therapeutic strategy in the case of invasive carcinomas.


   ACKNOWLEDGMENTS
 
We are grateful to Drs. N. Bachnou and D. D. Mousseau for critical reading of the manuscript and to L. Bourget, B. Paul Roc, and A. Bly for technical assistance. This is National Research Council Canada manuscript 41475. This work is dedicated to memory of my father, M. Al Moustafa.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Studies conducted in M. A. A-J.’s laboratory were supported by the Medical Research Council and the National Cancer Institute of Canada. Back

2 To whom requests for reprints should be addressed, at Biotechnology Research Institute, 6100 Royalmount Avenue, Montréal, Québec, H4P 2R2 Canada. Phone: (514) 496-6142; Fax: (514) 496-5143; E-mail: ala-eddin.al-moustafa{at}nrc.ca Back

3 The abbreviations used are: EGF-R, epidermal growth factor receptor; TGF-{alpha}, transforming growth factor-{alpha}; E-cadherin, epithelial cadherin glycoprotein; mAb, monoclonal antibody; NHBE, normal human bronchial epithelial; FBS, fetal bovine serum; KSFM, keratinocyte-SFM. Back

4 A-E. Al Moustafa, B. P. Roc, and M. O’Connor-McCourt, unpublished data. Back

5 A-E. Al Moustafa and M. O’Connor-McCourt, Epithelial-fibroblastoid cell conversion of an immortalized human bronchial epithelial cell line by epidermal growth factor (EGF) family members, submitted for publication. Back

6 A-E. Al Moustafa and M. O’Connor-McCourt, unpublished data. Back

Received 8/20/98; revised 12/ 2/98; accepted 12/ 7/98.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS AND DISCUSSION
 REFERENCES
 

  1. Gullick W. J. Type I growth factor receptors: current status and future work. Biochem. Soc. Symp. (Lond.), 63: 193-198, 1998.
  2. Cohen B. D., Siegall C. B., Bacus S., Foy L., Green J. M., Hellstrom I., Hellstrom K. E., Fell H. P. Role of epidermal growth factor receptor family members in growth and differentiation of breast carcinoma. Biochem. Soc. Symp. (Lond.), 63: 199-210, 1998.
  3. Liu C., Tsao M. S. Proto-oncogene and growth factor/receptor expression in the establishment of primary human non-small cell lung carcinoma cell lines. Am. J. Pathol., 142: 413-423, 1993.[Abstract]
  4. Chong I. W., Lin S. R., Lin M. S., Huang M. S., Tsai M. S., Hwang J. J. Heparin-binding epidermal growth factor-like growth factor and transforming growth factor-{alpha} in human non-small cell lung cancers. J. Formos. Med. Assoc., 96: 579-585, 1997.[Medline]
  5. Richardson G. E., Johnson B. E. The biology of lung cancer. Semin. Oncol., 20: 105-127, 1993.[Medline]
  6. Moody T. W. Peptides and growth factors in non-small cell lung cancer. Peptides, 17: 545-555, 1996.[Medline]
  7. Gill G. N., Kawamoto T., Cochet C., Le A., Sato J. D., Masui H., McLeod C., Mendelsohn J. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem., 259: 7755-7760, 1984.[Abstract/Free Full Text]
  8. Peng D., Fan Z., Lu Y., DeBlasio T., Scher H., Mendelsohn J. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1arrest in prostatic cancer cell line DU145. Cancer Res., 56: 3666-3669, 1996.[Abstract/Free Full Text]
  9. Hirsch T., Eggstein S., Frank S., Farthmann E., von Specht B. U. Autocrine growth stimulation of SW403 colon carcinoma cell line is caused by transforming-growth-factor-{alpha}-mediated epidermal growth factor receptor activation. J. Cancer Res. Clin. Oncol., 122: 328-334, 1996.[Medline]
  10. Teramoto T., Onda M., Tokunaga A., Asano G. Inhibitory effect of anti-epidermal growth factor receptor antibody on a human gastric cancer. Cancer (Phila.), 77: 1639-1645, 1996.[Medline]
  11. Masui H., Kawamoto T., Sato J. D., Wolf B., Sato G., Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res., 44: 1002-1007, 1984.[Abstract/Free Full Text]
  12. Fan Z., Mendelsohn J. Therapeutic application of anti-growth factor receptor antibodies. Curr. Opin. Oncol., 10: 67-73, 1998.[Medline]
  13. Takeichi M. Cadherins : a molecular family important in selective cell-cell adhesion. Annu. Rev. Biochem., 59: 237-252, 1990.[Medline]
  14. Berx G., Cleton-Jansen A. M., Nollet F., de Leeuw W. J., van de Vijver M., Cornelisse C., van Roy F. E-cadherin is a tumor/invasion suppressor gene mutated in human lobular breast cancers. EMBO J., 24: 6107-6115, 1995.
  15. Shiozaki H., Kadowaki T., Doki Y., Inoue M., Tamura S., Oka H., Iwazawa T., Matsui S., Shimaya K., Takeichi M., Mori T. Effect of epidermal growth factor on cadherin-mediated adhesion in a human oesophageal cancer cell line. Br. J. Cancer, 71: 250-258, 1995.[Medline]
  16. Fujii K., Furukawa F., Matsuyoshi N. Ligand activation of overexpressed epidermal growth factor receptor results in colony dissociation and disturbed E-cadherin function in HSC-1 human cutaneous squamous carcinoma cells. Exp. Cell Res., 223: 50-62, 1996.[Medline]
  17. Jones J. L., Royall J. E., Walker R. A. E-cadherin relates to EGFR expression and lymph node metastasis in primary breast carcinoma. Br. J. Cancer, 8: 1237-1241, 1996.
  18. Al Moustafa A-E., Chalifour L. E. Immortal cell lines isolated from heart differentiate to an endothelial cells lineage in the presence of retinoic acid. Cell Growth Differ., 4: 841-847, 1993.[Abstract]
  19. Tsao M. S., Zhu H., Viallet J. Autocrine growth loop of the epidermal growth factor receptor in normal and immortalized human bronchial epithelial cells. Exp. Cell Res., 223: 268-273, 1996.[Medline]
  20. Kawamoto T., Kishimoto K., Takahashi K., Matsumura T., Sato J. D., Taniguchi S. Polymorphonuclear leukocytes-mediated lysis of A431 cells induced by IgG1 mouse anti-epidermal growth factor receptor monoclonal antibodies. In Vitro Cell. Dev. Biol., 28A: 782-786, 1992.
  21. Solic N., Davies D. E. Differential effects of EGF and amphiregulin on adhesion molecule expression and migration of colon carcinoma cells. Exp. Cell Res., 234: 465-476, 1997.[Medline]
  22. Hodivala K. J, Watt F. M. Evidence that cadherins play a role in the down-regulation of integrin expression that occurs during keratinocyte terminal differentiation. J. Cell Biol., 124: 589-600, 1994.[Abstract/Free Full Text]
  23. Lewis J. E., Jensen P. J., Wheelock M. J. Cadherin function is required for human keratinocytes to assemble desmosomes and stratify in response to calcium. J. Invest. Dermatol., 102: 870-877, 1994.[Medline]
  24. Jiang W. G. E-cadherin and its associated protein catenins, cancer invasion and metastasis. Br. J. Surg., 83: 437-446, 1996.[Medline]
  25. Hoschuetzky H., Aberle H., Kemler R. ß-Catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J. Cell Biol., 127: 1375-1380, 1994.[Abstract/Free Full Text]
  26. Takahashi K., Suzuki K., Tsukatani Y. Induction of tyrosine phosphorylation and association of ß-catenin with EGF receptor upon tryptic digestion of quiescent cells at confluence. Oncogene, 15: 71-78, 1997.[Medline]
  27. Wu X., Rubin M., Fan Z., DeBlasio T., Soos T., Koff A., Mendelsohn J. Involvement of p27KIP1in G1arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene, 12: 1397-1403, 1996.[Medline]
  28. Hazan H., Norton L. The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton. J. Biol. Chem., 273: 9078-9084, 1998.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
D. A. Nikolova, I. A. Asangani, L. D. Nelson, D. P.M. Hughes, D. R. Siwak, G. B. Mills, A. Harms, E. Buchholz, L. R. Pilz, C. Manegold, et al.
Cetuximab Attenuates Metastasis and u-PAR Expression in Non-Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity
Cancer Res., March 15, 2009; 69(6): 2461 - 2470.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. M. Farley, D. E. Purdy, O. P. Ryabinina, P. Schneider, B. E. Magun, and M. S. Iordanov
Fas Ligand-induced Proinflammatory Transcriptional Responses in Reconstructed Human Epidermis: RECRUITMENT OF THE EPIDERMAL GROWTH FACTOR RECEPTOR AND ACTIVATION OF MAP KINASES
J. Biol. Chem., January 11, 2008; 283(2): 919 - 928.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. D. Woodworth, E. Michael, D. Marker, S. Allen, L. Smith, and M. Nees
Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment
Mol. Cancer Ther., April 1, 2005; 4(4): 650 - 658.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Matar, F. Rojo, R. Cassia, G. Moreno-Bueno, S. Di Cosimo, J. Tabernero, M. Guzman, S. Rodriguez, J. Arribas, J. Palacios, et al.
Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225): Superiority Over Single-Agent Receptor Targeting
Clin. Cancer Res., October 1, 2004; 10(19): 6487 - 6501.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. H. Lorch, J. Klessner, J. K. Park, S. Getsios, Y. L. Wu, M. S. Stack, and K. J. Green
Epidermal Growth Factor Receptor Inhibition Promotes Desmosome Assembly and Strengthens Intercellular Adhesion in Squamous Cell Carcinoma Cells
J. Biol. Chem., August 27, 2004; 279(35): 37191 - 37200.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
D. M. Nguyen, S. Desai, A. Chen, T. S. Weiser, and D. S. Schrump
Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin
Ann. Thorac. Surg., December 1, 2000; 70(6): 1853 - 1860.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Al Moustafa, A.-E.
Right arrow Articles by O’Connor-McCourt, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Al Moustafa, A.-E.
Right arrow Articles by O’Connor-McCourt, M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online